Abstract
Introduction: Exercise induced laryngeal obstruction (EILO) is a common cause of exertional breathing problems; however, we lack randomized studies to guide its treatment. Inhaled ipratopriumbromide (IB) is a muscarine-receptor antagonist with anticholinergic properties, used to treat bronchial obstruction in asthma. Case-reports have suggested that IB may relieve symptoms of EILO.
Aim: To study if inhaled IB reduces EILO symptoms and laryngeal obstruction.
Methods: We enrolled 20 individuals (14 females, age 12-25 years) with EILO diagnosed by continuous laryngoscopy performed during maximal treadmill exercise (CLE). The participants performed two subsequent CLE tests with ergospirometry and recieved inhaled IB before one of the CLE tests, in a randomized order. EILO symptoms was reported by BORG score, and laryngeal obstruction by CLE-score.
Results: All the participants ran to exhaustion on both test. Borg-score and CLE-score did not differ between tests with or without IB inhalation.
Conclusion: We found that IB did not influence EILO symptoms, CLE scores or measures of gas exchange during maximal exercise, and cannot advise its use in patients with EILO.
Without IB Mean (SD) | With IB Mean (SD) | Difference Mean (95 %CI) | |
CLE-score (0-12) | 3,98 (1,18) | 3,90 (1,33) | -0,1 (-0,5 - 0,3) |
Borg-score (0-10) | 7,85 (1,92) | 7,5 (2,1) | -0,4 (-1,1 - 0,3) |
Distance (m) | 833,4 (175,4) | 825,3 (185,4) | -8,1 (-43 - 27,3) |
CO2peak ml/kg/min | 46,1 (6,7) | 45,7 (7,8) | -0,4 (-1,9 - 1,1) |
HR | 187,1 (9,1) | 185,1 (7,7) | -1,2 (-3,9 - 1,6) |
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3307.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021